GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Action(s) initiated or orders passed

Regulatory & Legal View source PDF Explain this filing

GLAXO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.3%Reaction day

₹3292.80

prior close

₹3357.90

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.4%+4.9% vs market

Pharmaceuticals peers, median of 150sector+0.6%+4.7% vs sector

On the reaction day the stock moved 4.9 pts more than Nifty Midcap 150 and 4.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.0

15m

+0.1

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.3+0.4+4.9+0.6+4.7

Next day

+2.9+1.1+1.8+1.4+1.5

+2.0+0.9+1.1+1.4+0.6

-0.1+0.9-0.9+1.1-1.1

+0.2+1.0-0.8+1.3-1.1

-0.2+1.0-1.3+1.7-2.0

-1.0+0.6-1.6+0.8-1.8

15d

-4.9+0.5-5.4+3.8-8.8

-6.4-2.0-4.4+1.3-7.7

-15.9-4.1-11.8-3.7-12.2

-18.8-3.4-15.4-3.6-15.2

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

GlaxoSmithKline Pharmaceuticals has received an order dated 24 June 2025 from the Commissioner, CGST & CX, Appeals-II, Kolkata, raising a GST demand of Rs. 3.39 crore for the period April 2017 to March 2018. The demand comprises Rs. 1.69 crore in tax and Rs. 1.69 crore in penalty, with interest not yet quantified. The order relates to the disallowance of transitional credit (TRAN 1 and TRAN 2) claimed under GST. The company has stated there is no impact on its financial operations and is evaluating the order to take appropriate action, which may include further appeal.

Likely market impact

The demand is relatively small for a company of GSK's size and the company says it does not affect financial operations; the stock is unlikely to see material reaction, though investors should watch for further legal action.